Holen Sie sich die Stockscreener-App
28.27
4.27%
-1.26
Handel nachbörslich:
28.01
-0.26
-0.92%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$29.53
Offen:
$28.81
24-Stunden-Volumen:
1.97M
Relative Volume:
0.96
Marktkapitalisierung:
$2.61B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-13.86
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
-8.45%
1M Leistung:
-13.92%
6M Leistung:
+44.16%
1J Leistung:
+42.78%
1-Tages-Spanne:
$28.12
$29.16
1-Wochen-Bereich:
$28.12
$31.49
52-Wochen-Spanne:
$12.91
$42.13
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
28.27 | 2.72B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
How liquid is Travere Therapeutics Inc. stockJuly 2025 Volume & Daily Chart Pattern Signals - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
TVTX: FILSPARI drove record revenue and patient growth in 2025, with strong outlook for 2026 - TradingView
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
TVTX: 2025 revenue surged to $490.7M on FILSPARI growth; net loss narrowed and pipeline advanced - TradingView
Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss - Investing.com Canada
Travere: Fourth Quarter Financial Results Overview - Bitget
Travere: Q4 Earnings Snapshot - KVUE
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q4 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.38 - marketscreener.com
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Travere Therapeutics faces earnings test amid FSGS approval delay By Investing.com - Investing.com UK
Travere Therapeutics faces earnings test amid FSGS approval delay - Investing.com Australia
Stocks with rising relative price strength: Travere Therapeutics - MSN
Earnings Outlook For Travere Therapeutics - Benzinga
Aberdeen Group plc Acquires 70,791 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market - Finviz
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unpacking A 52.25% Potential Upside - DirectorsTalk Interviews
How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX) - Yahoo Finance
Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility? - Yahoo Finance
Precision Trading with Travere Therapeutics Inc. (TVTX) Risk Zones - Stock Traders Daily
15 Innovative Healthcare Stocks to Buy According to Analysts - Insider Monkey
Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts - MarketBeat
Can Travere Therapeutics Inc. be recession proofJuly 2025 Trade Ideas & Weekly High Conviction Ideas - mfd.ru
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.71%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):